2:05 PM · 27 September 2024

FDA approves Bristol Myers' innovative drug for schizophrenia 💡

Bristol Myers (BMY.US) shares are up 4% ahead of the week’s final session on Wall Street after the drugmaker won approval from the U.S. Food and Drug Administration for its novel drug Cobenfa as a treatment for schizophrenia in adults. Analysts have commented that the FDA approval could help Bristol approve its acquisition of Karuna Therapeutics, which would theoretically expand BMY’s sales capabilities.

The FDA-approved drug is notable for being the first antipsychotic drug to target cholinergic receptors rather than dopamine receptors, which could be safer for patients in some situations. It is the first approved drug for schizophrenia in 30 years.

 

The stock is gaining ahead of the open and is trading well above the 200-day EMA (golden line on the chart), which could define the overall trend in the stock over the long term. Source: xStatio

29 May 2026, 2:51 PM

US OPEN: Dell soars and keeps pushing tech stocks higher 🚀

29 May 2026, 10:08 AM

EU50 near record highs: broad-based gains and buybacks support european equities 🔎

29 May 2026, 7:12 AM

Dell surges 40% amid very strong earnings report ⚡The next AI winner?

28 May 2026, 7:12 PM

Daily Summary: Is the End of the War Drawing Near? (28.05.2026)

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits